Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Asset Writedowns and Impairment (2021 - 2025)

Lyell Immunopharma's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $1.4 million for Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 95.55%, while the annual FY2024 figure was $51.3 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q2 2025 was $1.4 million at Lyell Immunopharma, up from -$5.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $36.4 million in Q4 2021 and bottomed at -$5.0 million in Q4 2022.
  • The 3-year median for Asset Writedowns and Impairment is $1.4 million (2025), against an average of $10.9 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 113.72% in 2022 against a maximum downside of 113.72% in 2022.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $36.4 million in 2021, then tumbled by 113.72% to -$5.0 million in 2022, then skyrocketed by 128.0% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Asset Writedowns and Impairment are $1.4 million (Q2 2025), -$5.0 million (Q4 2022), and $36.4 million (Q4 2021).